Company intelligence / Profile preview

Shanghai Gebaide Biotechnology Co., Ltd.

Shanghai, Shanghai Shi, Chinamentalhealth.networkofcare.org ↗

Ownership: Private
Development stage: Phase 3

Overview

Shanghai Gebaide Biotechnology Co., Ltd. focuses on developing biologic therapeutics for oncology and respiratory diseases. Its lead asset, Dulanermin—a recombinant human Apo‑2 ligand acting as a TRAIL receptor agonist—is in Phase 3 development for advanced non-small cell lung cancer. The company appears to have a narrow pipeline focused on this single late-stage asset; no additional programs or broad technology platforms are publicly disclosed. Clinical results and further details require login access to proprietary databases.

Therapeutic areas: Oncology
Modalities: Recombinant proteins
Industry: Biotech

Drug pipeline

1 asset

recombinant human Apo-2 ligand

Phase 3

Indications: Non-small cell lung cancer

Beyond the preview

Go deeper on Shanghai Gebaide Biotechnology Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Gebaide Biotechnology Co., Ltd..

Explore the full profile